HK1121463A1 - Treatment of tnf alpha related disorders tnf - Google Patents
Treatment of tnf alpha related disorders tnfInfo
- Publication number
- HK1121463A1 HK1121463A1 HK09100383.6A HK09100383A HK1121463A1 HK 1121463 A1 HK1121463 A1 HK 1121463A1 HK 09100383 A HK09100383 A HK 09100383A HK 1121463 A1 HK1121463 A1 HK 1121463A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tnf
- treatment
- related disorders
- alpha related
- tnf alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39727502P | 2002-07-19 | 2002-07-19 | |
US41108102P | 2002-09-16 | 2002-09-16 | |
US41749002P | 2002-10-10 | 2002-10-10 | |
US45577703P | 2003-03-18 | 2003-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1121463A1 true HK1121463A1 (en) | 2009-04-24 |
Family
ID=30773676
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09100383.6A HK1121463A1 (en) | 2002-07-19 | 2005-12-21 | Treatment of tnf alpha related disorders tnf |
HK16103196.8A HK1215265A1 (zh) | 2002-07-19 | 2016-03-18 | α相關疾病的治療 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16103196.8A HK1215265A1 (zh) | 2002-07-19 | 2016-03-18 | α相關疾病的治療 |
Country Status (22)
Country | Link |
---|---|
US (16) | US20040136991A1 (de) |
EP (6) | EP2336182A1 (de) |
JP (4) | JP2006506465A (de) |
KR (6) | KR20050042466A (de) |
CN (4) | CN102755646A (de) |
AR (2) | AR040603A1 (de) |
AU (2) | AU2003267999B2 (de) |
BR (1) | BR0312785A (de) |
CA (4) | CA2493067A1 (de) |
DK (1) | DK1944322T3 (de) |
ES (1) | ES2535365T3 (de) |
HK (2) | HK1121463A1 (de) |
IL (4) | IL166280A (de) |
MX (2) | MX342777B (de) |
MY (2) | MY151032A (de) |
NZ (5) | NZ555692A (de) |
PL (3) | PL217223B1 (de) |
PT (1) | PT1944322E (de) |
SI (1) | SI1944322T1 (de) |
TW (3) | TWI430810B (de) |
WO (1) | WO2004009776A2 (de) |
ZA (1) | ZA200500068B (de) |
Families Citing this family (186)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
CN101712720A (zh) * | 1996-02-09 | 2010-05-26 | 艾博特生物技术有限公司 | 结合人TNFα的人抗体 |
US7115557B2 (en) * | 1998-09-25 | 2006-10-03 | Sciaticon Ab | Use of certain drugs for treating nerve root injury |
US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20060241074A1 (en) * | 2001-08-14 | 2006-10-26 | The General Hospital Corporation | Methods for treatment of pain |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
KR20050042466A (ko) * | 2002-07-19 | 2005-05-09 | 애보트 바이오테크놀로지 리미티드 | TNFα 관련 질환의 치료 |
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
US20040253237A1 (en) * | 2002-12-05 | 2004-12-16 | Ian Walters | Methods of treatment of ulcerative colitis with anti-CD3 antibodies |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
PT1606261E (pt) | 2003-03-10 | 2010-01-11 | Nycomed Gmbh | Novo processo para a preparação de roflumilast |
JP4565193B2 (ja) * | 2003-04-23 | 2010-10-20 | バレリタス, インコーポレイテッド | 長い持続時間の医薬投与のための液圧作動式ポンプ |
US7553827B2 (en) * | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
US8273347B2 (en) * | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
US7344716B2 (en) * | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
US20040229878A1 (en) * | 2003-05-13 | 2004-11-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of P38 kinase |
US7429378B2 (en) * | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
US8361467B2 (en) * | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
BRPI0413326A (pt) * | 2003-08-04 | 2006-10-10 | Bristol Myers Squibb Co | métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel |
US7396819B2 (en) * | 2003-08-08 | 2008-07-08 | Virbac Corporation | Anthelmintic formulations |
US20070208057A1 (en) * | 2003-11-06 | 2007-09-06 | Zeldis Jerome B | Methods And Compositions Using Thalidomide For The Treatment And Management Of Cancers And Other Diseases |
US8895540B2 (en) * | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
WO2005094210A2 (en) * | 2004-03-12 | 2005-10-13 | The Hartz Mountain Corporation | Multi-action anthelmintic formulations |
TW201705980A (zh) | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療TNFα相關失調症之多重可變劑量療法 |
GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
US9089636B2 (en) | 2004-07-02 | 2015-07-28 | Valeritas, Inc. | Methods and devices for delivering GLP-1 and uses thereof |
US20060046961A1 (en) * | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
US20060205669A1 (en) * | 2004-09-16 | 2006-09-14 | The Regents Of The University Of California | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
DE102004046235A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
US20060083741A1 (en) * | 2004-10-08 | 2006-04-20 | Hoffman Rebecca S | Treatment of respiratory syncytial virus (RSV) infection |
AU2005314043A1 (en) | 2004-12-06 | 2006-06-15 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
CA2601250C (en) * | 2005-03-16 | 2014-10-28 | Nycomed Gmbh | Taste masked dosage form containing roflumilast |
US7431927B2 (en) | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
AU2006230419A1 (en) * | 2005-03-31 | 2006-10-05 | Targeted Genetics Corporation | Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
AU2006242651B2 (en) * | 2005-04-29 | 2013-05-16 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
CN101500607B (zh) | 2005-05-16 | 2013-11-27 | 阿布维生物技术有限公司 | TNFα抑制剂治疗腐蚀性多关节炎的用途 |
AU2012254978C1 (en) * | 2005-05-16 | 2017-06-01 | Abbvie Biotechnology Ltd | Use of TNF inhibitor for treatment of erosive polyarthritis |
WO2007050130A2 (en) * | 2005-06-03 | 2007-05-03 | Biohesion, Inc. | Gold surfaces coated with a thermostable, chemically resistant polypeptide layer and applications thereof |
EA012801B1 (ru) | 2005-06-14 | 2009-12-30 | Эмджен Инк. | Самобуферирующиеся композиции белков |
US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
US20070072247A1 (en) * | 2005-08-31 | 2007-03-29 | Academia Sinica | Methods and reagents for the analysis and purification of polysaccharides |
US7943134B2 (en) * | 2005-08-31 | 2011-05-17 | Academia Sinica | Compositions and methods for identifying response targets and treating flavivirus infection responses |
WO2007089303A2 (en) * | 2005-11-01 | 2007-08-09 | Abbott Biotechnology Ltd. | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
KR20140087058A (ko) | 2005-11-30 | 2014-07-08 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
PT2289909E (pt) | 2005-11-30 | 2015-02-10 | Abbvie Inc | Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos |
US8795668B2 (en) * | 2005-12-23 | 2014-08-05 | The Regents Of The University Of Michigan | Methods for treating pulmonary fibrosis |
EP2982399B1 (de) | 2006-03-30 | 2017-12-06 | Valeritas, Inc. | Flüssigkeitsausgabevorrichtung mit mehreren kartuschen |
NZ611859A (en) * | 2006-04-05 | 2014-12-24 | Abbvie Biotechnology Ltd | Antibody purification |
US9605064B2 (en) * | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
EP2012824A4 (de) * | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | Anwendungen und zusammensetzungen zur behandlung von schuppenflechte |
US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
EP2012586A4 (de) | 2006-04-10 | 2010-08-18 | Abbott Biotech Ltd | Anwendungen und zusammensetzungen zur behandlung von morbus bechterew |
WO2008063213A2 (en) | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
US8277809B2 (en) * | 2006-04-21 | 2012-10-02 | Centocor, Inc. | CXCL13 antagonists and their use for the treatment of inflammatory diseases |
US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
BRPI0713802A2 (pt) | 2006-06-30 | 2012-11-06 | Abbott Biotech Ltd | dispositivo de injeção automático |
CA2667655A1 (en) * | 2006-10-27 | 2008-05-15 | Abbott Biotechnology Ltd. | Crystalline anti-htnfalpha antibodies |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
CN101200465B (zh) * | 2006-12-11 | 2010-12-29 | 和记黄埔医药(上海)有限公司 | 一种十氢化萘类化合物及其医药用途 |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
RU2476442C2 (ru) | 2007-03-29 | 2013-02-27 | Эббот Лэборетриз | Кристаллические антитела против il-12 человека |
US20080254011A1 (en) * | 2007-04-11 | 2008-10-16 | Peter Rothschild | Use of selected lactic acid bacteria for reducing atherosclerosis |
WO2008141511A1 (fr) * | 2007-05-22 | 2008-11-27 | Human Antibodomics (Shanghai) Inc. | ANTICORPS MONOCLONAL HUMAIN ANTI-TNFα ET SON UTILISATION |
EP2165194A4 (de) * | 2007-05-31 | 2010-09-08 | Abbott Lab | Biomarker zur vorhersage der ansprechbarkeit auf tnf-alpha-inhibitoren bei autoimmunkrankheiten |
EP2171451A4 (de) | 2007-06-11 | 2011-12-07 | Abbott Biotech Ltd | Verfahren zur behandlung juveniler idiopathischer arthritis |
EP2173380A4 (de) * | 2007-07-13 | 2011-08-31 | Abbott Biotech Ltd | VERFAHREN UND ZUSAMMENSETZUNGEN ZUR PULMONALEN VERABREICHUNG EINES TNFa-HEMMERS |
EP2184997A4 (de) * | 2007-07-31 | 2010-11-03 | Univ New York | Diagnose- und behandlungsverfahren für die charakterisierung von bakteriellen mikroorganismen bei hautkrankheiten |
CN101980722A (zh) * | 2007-08-08 | 2011-02-23 | 雅培制药有限公司 | 结晶抗体的组合物和方法 |
US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
AU2008296478B9 (en) | 2007-08-28 | 2015-03-19 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
US20090098136A1 (en) * | 2007-10-15 | 2009-04-16 | Alcon Research, Ltd. | Use of tnf receptor antagonists for treating dry eye |
US20090170770A1 (en) * | 2007-11-06 | 2009-07-02 | Ali Hafezi-Moghadam | Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
CA2904458C (en) | 2007-11-30 | 2017-07-25 | Wolfgang Fraunhofer | Protein formulations and methods of making same |
US8986696B2 (en) * | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
US20090162351A1 (en) * | 2007-12-21 | 2009-06-25 | Depuy Spine, Inc. | Transdiscal administration of inhibitors of p38 MAP kinase |
JP2011510267A (ja) * | 2008-01-03 | 2011-03-31 | アボツト・バイオテクノロジー・リミテツド | 乾癬の治療における化合物の長期的効力の予測 |
SG187473A1 (en) | 2008-01-15 | 2013-02-28 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
US9365644B2 (en) * | 2008-04-23 | 2016-06-14 | Epitomics, Inc. | Anti-TNFα antibody |
SG10201702922VA (en) * | 2008-10-20 | 2017-06-29 | Abbvie Inc | Isolation and purification of antibodies using protein a affinity chromatography |
KR20110138412A (ko) * | 2009-04-16 | 2011-12-27 | 애보트 바이오테라퓨틱스 코포레이션 | 항-ΤΝF-α 항체 및 그의 용도 |
US8636704B2 (en) | 2009-04-29 | 2014-01-28 | Abbvie Biotechnology Ltd | Automatic injection device |
NZ595694A (en) * | 2009-05-04 | 2013-09-27 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
NZ600069A (en) | 2009-12-15 | 2015-02-27 | Abbvie Biotechnology Ltd | Improved firing button for automatic injection device |
WO2011084714A2 (en) * | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
NZ602782A (en) | 2010-04-21 | 2015-07-31 | Abbvie Biotechnology Ltd | Wearable automatic injection device for controlled delivery of therapeutic agents |
US8747854B2 (en) | 2010-06-03 | 2014-06-10 | Abbvie Biotechnology Ltd. | Methods of treating moderate to severe hidradenitis suppurativa with anti-TNF-alpha antibodies |
MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
MX344727B (es) | 2010-11-11 | 2017-01-05 | Abbvie Biotechnology Ltd | Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. |
EP2749305B1 (de) | 2011-01-24 | 2017-11-01 | AbbVie Biotechnology Ltd | Automatische Injektionsvorrichtungen mit umspritzten Greifflächen |
US9387195B2 (en) | 2011-03-07 | 2016-07-12 | Celgene Corporation | Methods for treating diseases using isoindoline compounds |
SG10201604560TA (en) * | 2011-04-12 | 2016-07-28 | Moerae Matrix Inc | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
EP2702077A2 (de) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen |
EP2758068A1 (de) * | 2011-09-23 | 2014-07-30 | Westfälische Wilhelms-Universität Münster | Yersinia outer protein m (yopm) bei der behandlung von psoriasis |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
WO2013191352A1 (en) | 2012-06-21 | 2013-12-27 | Hanall Biopharma Co., Ltd. | New uses of modified human tumor necrosis factor receptor-1 polypeptide |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
US9206390B2 (en) | 2012-09-02 | 2015-12-08 | Abbvie, Inc. | Methods to control protein heterogeneity |
EP4005582A1 (de) * | 2012-10-22 | 2022-06-01 | Stealth BioTherapeutics Inc. | Behandlung von linksventrikulärer remodellierung |
US20140255403A1 (en) * | 2013-03-06 | 2014-09-11 | Hadasit Medical Research Services & Development Ltd. | Oral composition comprising a tnf antagonist and use thereof |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
BR112015023699A2 (pt) * | 2013-03-15 | 2017-07-18 | Intermune Inc | método de determinação de um nível de expressão de uma proteína marcadora de doença pulmonar fibrótica, método de determinação se um indivíduo tem ou está em risco de desenvolvimento de uma doença pulmonar fibrótica, método de determinação se um paciente de doença pulmonar fibrótica está em risco de progressão da doença pulmonar fibrótica, método de determinação de uma atividade de doença pulmonar fibrótica em um paciente, e método de tratamento de uma doença pulmonar fibrótica em um indivíduo em necessidade do mesmo |
TWI516272B (zh) * | 2013-06-05 | 2016-01-11 | 財團法人工業技術研究院 | 應用於生髮之方法及醫藥組成物 |
CN104341502B (zh) * | 2013-08-09 | 2016-04-27 | 北京天成新脉生物技术有限公司 | 低免疫原性抗TNF-α全人源单抗及其应用 |
PL226431B1 (pl) | 2013-08-23 | 2017-07-31 | Inst Biochemii I Biofizyki Polskiej Akademii Nauk | Cząsteczka miRNA do zastosowania do wytwarzania leku do zmniejszania reakcji zapalnej lub zapobiegania zwiększaniu się reakcji zapalnej organizmu |
EP3052640A2 (de) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine |
CA2926588C (en) | 2013-10-16 | 2020-07-21 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
CN103961694A (zh) * | 2014-04-18 | 2014-08-06 | 陶惠人 | 基于p-硝基苯丙氨酸插入法构建的骨质疏松疫苗 |
US9580495B2 (en) | 2014-06-24 | 2017-02-28 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
US10351621B2 (en) | 2014-06-24 | 2019-07-16 | Immunomedics, Inc. | Anti-histone therapy in acute kidney injury |
US10080877B2 (en) | 2014-07-25 | 2018-09-25 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a drug cartridge |
US9775978B2 (en) | 2014-07-25 | 2017-10-03 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
US10653747B2 (en) | 2014-07-31 | 2020-05-19 | Uab Research Foundation | ApoE mimetic peptides and higher potency to clear plasma cholesterol |
RU2020141422A (ru) | 2014-11-05 | 2021-01-13 | Дженентек, Инк. | Способы получения двуцепочечных белков в бактериях |
JP6875276B2 (ja) * | 2014-11-05 | 2021-05-19 | ジェネンテック, インコーポレイテッド | 細菌における2鎖タンパク質の生成方法 |
CA3005158A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
EP3227880B1 (de) * | 2014-12-01 | 2018-09-26 | Truinject Corp. | Trainingsvorrichtung für injektionen mit rundstrahllichtemission |
EP3247718B1 (de) | 2015-01-21 | 2021-09-01 | Outlook Therapeutics, Inc. | Modulation von ladungsvarianten in einer monoklonalen antikörperzusammensetzung |
US10465224B2 (en) | 2015-02-03 | 2019-11-05 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing and treating arthritis |
IL254577B2 (en) | 2015-03-31 | 2023-11-01 | Vhsquared Ltd | polypeptides |
EP3078675A1 (de) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induktionsdosierschema zur behandlung von krankheiten die von tnf alpha verursacht sind |
WO2016201409A1 (en) * | 2015-06-12 | 2016-12-15 | Georgia State University Research Foundation | Compositions and methods for treating opioid tolerance |
CN105175529A (zh) * | 2015-07-16 | 2015-12-23 | 中国科学院海洋研究所 | 一种鱼类肿瘤坏死因子家族蛋白的重组蛋白及其应用 |
AU2016297248A1 (en) * | 2015-07-22 | 2018-02-15 | Scholar Rock, Inc. | GDF11 binding proteins and uses thereof |
IL258121B2 (en) | 2015-09-15 | 2024-01-01 | Scholar Rock Inc | Antipro/latent myostatin antibodies and their uses |
US10076650B2 (en) | 2015-11-23 | 2018-09-18 | Warsaw Orthopedic, Inc. | Enhanced stylet for drug depot injector |
MX2018008369A (es) | 2016-01-08 | 2019-05-15 | Scholar Rock Inc | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. |
CN109563161A (zh) | 2016-02-03 | 2019-04-02 | 安口生物公司 | 用于提高抗体稳定性的缓冲制剂 |
US10465003B2 (en) * | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
EP3785728A3 (de) | 2016-06-13 | 2021-04-28 | Scholar Rock, Inc. | Verwendung von myostatininhibitoren und kombinationstherapien |
US10549081B2 (en) | 2016-06-23 | 2020-02-04 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
US20190202907A1 (en) * | 2016-09-02 | 2019-07-04 | 180 Therapeutics Lp | Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody |
WO2018045258A1 (en) * | 2016-09-02 | 2018-03-08 | The University Of Chicago | TREATMENT OF TNF-alpha CYTOTOXICITY |
EP3519438A1 (de) | 2016-09-30 | 2019-08-07 | VHsquared Limited | Zusammensetzungen |
EP3528787A4 (de) | 2016-10-21 | 2020-05-06 | Amgen Inc. | Pharmazeutische formulierungen und verfahren zur herstellung davon |
US10434261B2 (en) | 2016-11-08 | 2019-10-08 | Warsaw Orthopedic, Inc. | Drug pellet delivery system and method |
MX2019006864A (es) * | 2016-12-14 | 2019-10-15 | Progenity Inc | Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de factor de necrosis tumoral (tnf). |
DK3565592T3 (da) | 2017-01-06 | 2023-05-01 | Scholar Rock Inc | Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering |
KR101946884B1 (ko) * | 2017-04-25 | 2019-02-13 | 고려대학교 산학협력단 | 대사체 분석을 이용한 베체트병의 진단방법 |
US11097067B2 (en) * | 2017-04-25 | 2021-08-24 | Cc Biotechnology Corporation | Injection pen |
WO2018226991A1 (en) | 2017-06-07 | 2018-12-13 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
CN107362351B (zh) * | 2017-09-04 | 2020-11-10 | 上海市儿童医院 | Il-36r的拮抗剂在制备镇痛药物中的应用 |
CN111556763B (zh) | 2017-11-13 | 2023-09-01 | 施菲姆德控股有限责任公司 | 血管内流体运动装置、系统 |
EP4085965A1 (de) | 2018-02-01 | 2022-11-09 | Shifamed Holdings, LLC | Intravaskuläre blutpumpen und verfahren zur verwendung und herstellung |
CN108588040B (zh) * | 2018-06-08 | 2021-06-15 | 中国医学科学院病原生物学研究所 | 重组MtMetRS、其晶体及它们在制备抗结核药物中的应用 |
JP2021530553A (ja) * | 2018-07-25 | 2021-11-11 | ラッシュ ユニバーシティ メディカル センターRush University Medical Center | 標的サイトカイン枯渇による腎臓病の再発の抑制 |
WO2020086934A2 (en) | 2018-10-26 | 2020-04-30 | Abbott Diabetes Care Inc. | Methods, devices, and systems for physiological parameter analysis |
CN109998488B (zh) * | 2019-04-13 | 2022-08-02 | 中国医学科学院北京协和医院 | 克罗恩病和肠道溃疡型淋巴瘤的鉴别模型及构建方法 |
BR112021025416A2 (pt) * | 2019-06-17 | 2022-02-22 | Mayo Found Medical Education & Res | Preparações de prevotella e tratamento de doença pulmonar obstrutiva crônica (dpoc) e outras condições pulmonares |
JP2022537780A (ja) | 2019-06-21 | 2022-08-29 | ソリッソ ファーマシューティカルズ,インク. | ポリペプチド |
JP2022538083A (ja) | 2019-06-21 | 2022-08-31 | ソリッソ ファーマシューティカルズ,インク. | ポリペプチド |
US11964145B2 (en) | 2019-07-12 | 2024-04-23 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of manufacture and use |
US11654275B2 (en) | 2019-07-22 | 2023-05-23 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
CN114980901A (zh) * | 2019-08-30 | 2022-08-30 | 挪威西部创新股份有限公司 | 使用针对浆细胞的抑制剂或细胞毒性剂治疗慢性疲劳综合征的方法 |
EP4034192A4 (de) | 2019-09-25 | 2023-11-29 | Shifamed Holdings, LLC | Intravaskuläre blutpumpensysteme und verfahren zur verwendung und steuerung davon |
TWI807338B (zh) * | 2020-06-26 | 2023-07-01 | 美商美國禮來大藥廠 | 結合TGF-α及表皮調節素(EPIREGULIN)之抗體於治療疼痛之用途 |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6448A (en) | 1849-05-15 | Improvement in cut-offs and steam-stops of rotary engines | ||
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
DE3631229A1 (de) * | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
US6498237B2 (en) * | 1989-08-07 | 2002-12-24 | Peptech Limited | Tumor necrosis factor antibodies |
US5959087A (en) * | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
FR2651130B1 (fr) * | 1989-08-23 | 1991-12-13 | Roussel Uclaf | Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques. |
AU630497B2 (en) | 1989-09-05 | 1992-10-29 | Immunex Corporation | Tumor necrosis factor-alpha and -beta receptors |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US20020099179A1 (en) * | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
EP0575485A1 (de) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Verfahren zur entwicklung bindender miniproteine |
CA2106299C (en) * | 1991-03-18 | 2001-02-06 | Junming Le | Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
US20070298040A1 (en) * | 1991-03-18 | 2007-12-27 | Centocor, Inc. | Methods of treating seronegative arthropathy with anti-TNF antibodies |
US20060246073A1 (en) * | 1991-03-18 | 2006-11-02 | Knight David M | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US20040120952A1 (en) * | 2000-08-07 | 2004-06-24 | Centocor, Inc | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
WO1992018619A1 (en) | 1991-04-10 | 1992-10-29 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
WO1993019751A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
AU670125B2 (en) | 1992-09-15 | 1996-07-04 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
DK0614984T4 (da) * | 1993-03-05 | 2010-12-20 | Bayer Healthcare Llc | Humane monoklonale anti-TNF-alfa-antistoffer |
NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
CA2245800A1 (en) * | 1996-02-08 | 1997-08-14 | Warwick Andrew Mckenzie | Lockable coupling |
CN101712720A (zh) * | 1996-02-09 | 2010-05-26 | 艾博特生物技术有限公司 | 结合人TNFα的人抗体 |
ATE211740T1 (de) * | 1996-06-27 | 2002-01-15 | Pfizer | Substituierte indazolderivate |
CN1114604C (zh) * | 1996-11-15 | 2003-07-16 | 达尔文发现有限公司 | 双环芳基甲酰胺及其治疗应用 |
WO1998051344A1 (en) * | 1997-05-12 | 1998-11-19 | The Kennedy Institute Of Rheumatology | Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy |
JPH11127882A (ja) * | 1997-10-27 | 1999-05-18 | Nippon Kayaku Co Ltd | 新規生理活性物質nk30424a,nk30424b,それらの製造法およびそれらの用途 |
US6419944B2 (en) * | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
US6537549B2 (en) * | 1999-02-24 | 2003-03-25 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
US6423321B2 (en) * | 1999-02-24 | 2002-07-23 | Edward L. Tobinick | Cytokine antagonists for the treatment of sensorineural hearing loss |
US6379666B1 (en) * | 1999-02-24 | 2002-04-30 | Edward L. Tobinick | TNF inhibitors for the treatment of neurological, retinal and muscular disorders |
DK1041072T3 (da) * | 1999-03-31 | 2003-11-10 | Pfizer Prod Inc | Dioxocyclopentylhydroxamsyrer |
US20010021380A1 (en) * | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
US6833268B1 (en) * | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
AU3082401A (en) * | 1999-11-24 | 2001-06-04 | Centocor Inc. | Therapy of psoriasis |
JP4812921B2 (ja) * | 2000-04-14 | 2011-11-09 | 田辺三菱製薬株式会社 | ベーチェット病治療剤 |
GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
US20060018907A1 (en) * | 2000-08-07 | 2006-01-26 | Centocor, Inc. | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US20050249735A1 (en) * | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
KR20100031769A (ko) * | 2000-12-28 | 2010-03-24 | 알투스 파마슈티컬스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
WO2002096461A1 (en) * | 2001-05-25 | 2002-12-05 | Abbott Gmbh & Co. Kg | Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients |
CA2817619A1 (en) * | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20030161828A1 (en) * | 2002-02-19 | 2003-08-28 | Abbott Gmbh & Co. Kg | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure |
US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20030206898A1 (en) * | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
KR20050042466A (ko) * | 2002-07-19 | 2005-05-09 | 애보트 바이오테크놀로지 리미티드 | TNFα 관련 질환의 치료 |
US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
KR20050086628A (ko) * | 2002-11-15 | 2005-08-30 | 젠맵 에이/에스 | Cd25에 대한 인간 모노클로날 항체 |
US7101978B2 (en) * | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
US20040193466A1 (en) * | 2003-03-27 | 2004-09-30 | Irena Kull | Method and process for managing a yard |
TW201705980A (zh) * | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療TNFα相關失調症之多重可變劑量療法 |
US20060083741A1 (en) * | 2004-10-08 | 2006-04-20 | Hoffman Rebecca S | Treatment of respiratory syncytial virus (RSV) infection |
CN101500607B (zh) * | 2005-05-16 | 2013-11-27 | 阿布维生物技术有限公司 | TNFα抑制剂治疗腐蚀性多关节炎的用途 |
US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
WO2007089303A2 (en) * | 2005-11-01 | 2007-08-09 | Abbott Biotechnology Ltd. | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
NZ611859A (en) * | 2006-04-05 | 2014-12-24 | Abbvie Biotechnology Ltd | Antibody purification |
EP2012586A4 (de) * | 2006-04-10 | 2010-08-18 | Abbott Biotech Ltd | Anwendungen und zusammensetzungen zur behandlung von morbus bechterew |
US9399061B2 (en) * | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
WO2008063213A2 (en) * | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
US20100021451A1 (en) * | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
BRPI0713802A2 (pt) * | 2006-06-30 | 2012-11-06 | Abbott Biotech Ltd | dispositivo de injeção automático |
KR20090074040A (ko) * | 2006-09-13 | 2009-07-03 | 아보트 러보러터리즈 | 세포 배양의 개선 |
CA2667655A1 (en) * | 2006-10-27 | 2008-05-15 | Abbott Biotechnology Ltd. | Crystalline anti-htnfalpha antibodies |
EP2165194A4 (de) * | 2007-05-31 | 2010-09-08 | Abbott Lab | Biomarker zur vorhersage der ansprechbarkeit auf tnf-alpha-inhibitoren bei autoimmunkrankheiten |
WO2008150490A2 (en) * | 2007-06-01 | 2008-12-11 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriasis and crohn's disease |
EP2171451A4 (de) * | 2007-06-11 | 2011-12-07 | Abbott Biotech Ltd | Verfahren zur behandlung juveniler idiopathischer arthritis |
EP2173380A4 (de) * | 2007-07-13 | 2011-08-31 | Abbott Biotech Ltd | VERFAHREN UND ZUSAMMENSETZUNGEN ZUR PULMONALEN VERABREICHUNG EINES TNFa-HEMMERS |
CN101980722A (zh) * | 2007-08-08 | 2011-02-23 | 雅培制药有限公司 | 结晶抗体的组合物和方法 |
CA2904458C (en) * | 2007-11-30 | 2017-07-25 | Wolfgang Fraunhofer | Protein formulations and methods of making same |
JP2011510267A (ja) * | 2008-01-03 | 2011-03-31 | アボツト・バイオテクノロジー・リミテツド | 乾癬の治療における化合物の長期的効力の予測 |
KR20100113112A (ko) * | 2008-01-15 | 2010-10-20 | 아보트 러보러터리즈 | 개선된 포유동물 발현 벡터 및 이의 용도 |
SG187473A1 (en) * | 2008-01-15 | 2013-02-28 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
EP2271671A2 (de) * | 2008-03-24 | 2011-01-12 | Abbott Biotechnology Ltd. | Tnf-alpha-inhibitoren zur behandlung von knochenverlust |
US8550074B2 (en) * | 2009-01-15 | 2013-10-08 | Manta Devices, Llc | Delivery device and related methods |
US8636704B2 (en) * | 2009-04-29 | 2014-01-28 | Abbvie Biotechnology Ltd | Automatic injection device |
NZ595694A (en) * | 2009-05-04 | 2013-09-27 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
-
2003
- 2003-07-18 KR KR1020057001064A patent/KR20050042466A/ko not_active Application Discontinuation
- 2003-07-18 US US10/623,075 patent/US20040136991A1/en not_active Abandoned
- 2003-07-18 SI SI200332414T patent/SI1944322T1/sl unknown
- 2003-07-18 DK DK07150442.7T patent/DK1944322T3/da active
- 2003-07-18 CN CN2012102392380A patent/CN102755646A/zh active Pending
- 2003-07-18 PL PL397846A patent/PL217223B1/pl unknown
- 2003-07-18 AR AR20030102605A patent/AR040603A1/es not_active Application Discontinuation
- 2003-07-18 EP EP10182274A patent/EP2336182A1/de not_active Ceased
- 2003-07-18 CA CA002493067A patent/CA2493067A1/en not_active Abandoned
- 2003-07-18 KR KR1020147007746A patent/KR20140058649A/ko not_active Application Discontinuation
- 2003-07-18 PT PT71504427T patent/PT1944322E/pt unknown
- 2003-07-18 US US10/622,928 patent/US20040151722A1/en not_active Abandoned
- 2003-07-18 US US10/623,065 patent/US20040126373A1/en not_active Abandoned
- 2003-07-18 KR KR20157009634A patent/KR20150043568A/ko not_active Application Discontinuation
- 2003-07-18 MY MYPI20032713 patent/MY151032A/en unknown
- 2003-07-18 EP EP10182730A patent/EP2371859A3/de not_active Withdrawn
- 2003-07-18 CN CN200910253363A patent/CN101745112A/zh active Pending
- 2003-07-18 CA CA2803741A patent/CA2803741A1/en not_active Withdrawn
- 2003-07-18 ES ES07150442.7T patent/ES2535365T3/es not_active Expired - Lifetime
- 2003-07-18 KR KR1020127001635A patent/KR101283877B1/ko active IP Right Review Request
- 2003-07-18 US US10/622,205 patent/US20040219142A1/en not_active Abandoned
- 2003-07-18 TW TW098127343A patent/TWI430810B/zh not_active IP Right Cessation
- 2003-07-18 MX MX2009003691A patent/MX342777B/es unknown
- 2003-07-18 CN CN2012102392802A patent/CN102764436A/zh active Pending
- 2003-07-18 WO PCT/US2003/022566 patent/WO2004009776A2/en active Application Filing
- 2003-07-18 CA CA2880296A patent/CA2880296A1/en not_active Abandoned
- 2003-07-18 NZ NZ555692A patent/NZ555692A/en not_active IP Right Cessation
- 2003-07-18 US US10/622,932 patent/US20040126372A1/en not_active Abandoned
- 2003-07-18 US US10/623,318 patent/US20130243786A1/en not_active Abandoned
- 2003-07-18 CN CNA038224550A patent/CN1691963A/zh active Pending
- 2003-07-18 KR KR1020117004851A patent/KR20110027851A/ko not_active Application Discontinuation
- 2003-07-18 TW TW092119891A patent/TWI354561B/zh not_active IP Right Cessation
- 2003-07-18 PL PL401886A patent/PL218992B1/pl unknown
- 2003-07-18 TW TW101135423A patent/TWI527592B/zh not_active IP Right Cessation
- 2003-07-18 NZ NZ587754A patent/NZ587754A/en not_active IP Right Cessation
- 2003-07-18 US US10/623,035 patent/US20040136990A1/en not_active Abandoned
- 2003-07-18 MX MXPA05000815A patent/MXPA05000815A/es active IP Right Grant
- 2003-07-18 NZ NZ598346A patent/NZ598346A/xx not_active IP Right Cessation
- 2003-07-18 MY MYPI2013004323A patent/MY169308A/en unknown
- 2003-07-18 NZ NZ563452A patent/NZ563452A/en not_active IP Right Cessation
- 2003-07-18 EP EP07150442.7A patent/EP1944322B1/de not_active Revoked
- 2003-07-18 US US10/622,210 patent/US20040136989A1/en not_active Abandoned
- 2003-07-18 JP JP2005505532A patent/JP2006506465A/ja not_active Withdrawn
- 2003-07-18 PL PL374865A patent/PL213925B1/pl unknown
- 2003-07-18 CA CA2800126A patent/CA2800126A1/en not_active Abandoned
- 2003-07-18 KR KR1020127030281A patent/KR20130001318A/ko not_active IP Right Cessation
- 2003-07-18 AU AU2003267999A patent/AU2003267999B2/en not_active Expired
- 2003-07-18 BR BR0312785-0A patent/BR0312785A/pt not_active Application Discontinuation
- 2003-07-18 EP EP15157149.4A patent/EP2942359A1/de not_active Withdrawn
- 2003-07-18 EP EP10183702A patent/EP2298810A3/de not_active Withdrawn
- 2003-07-18 US US10/623,076 patent/US20040131614A1/en not_active Abandoned
- 2003-07-18 EP EP03748949A patent/EP1542720A4/de not_active Withdrawn
- 2003-07-18 US US10/623,039 patent/US20070202104A1/en not_active Abandoned
-
2005
- 2005-01-04 ZA ZA2005/00068A patent/ZA200500068B/en unknown
- 2005-01-13 IL IL166280A patent/IL166280A/en active IP Right Grant
- 2005-12-21 HK HK09100383.6A patent/HK1121463A1/xx not_active IP Right Cessation
-
2008
- 2008-04-14 US US12/102,682 patent/US20080193466A1/en not_active Abandoned
-
2009
- 2009-05-06 NZ NZ576774A patent/NZ576774A/en not_active IP Right Cessation
-
2010
- 2010-02-25 AU AU2010200708A patent/AU2010200708B2/en not_active Expired
- 2010-03-15 JP JP2010057713A patent/JP2010209070A/ja active Pending
- 2010-07-14 AR ARP100102563A patent/AR077474A2/es not_active Application Discontinuation
- 2010-12-19 IL IL210090A patent/IL210090A0/en unknown
- 2010-12-19 IL IL210091A patent/IL210091A/en active IP Right Grant
-
2011
- 2011-06-06 IL IL213400A patent/IL213400A0/en unknown
-
2012
- 2012-10-11 JP JP2012225755A patent/JP2013056892A/ja not_active Withdrawn
-
2013
- 2013-05-28 US US13/903,525 patent/US20130243763A1/en not_active Abandoned
-
2014
- 2014-05-02 US US14/268,449 patent/US20140286939A1/en not_active Abandoned
- 2014-05-02 US US14/268,614 patent/US20140286940A1/en not_active Abandoned
- 2014-05-02 US US14/268,628 patent/US20140286941A1/en not_active Abandoned
-
2015
- 2015-06-09 JP JP2015116695A patent/JP2015221798A/ja active Pending
- 2015-09-03 US US14/844,578 patent/US20150368335A1/en not_active Abandoned
-
2016
- 2016-03-18 HK HK16103196.8A patent/HK1215265A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1215265A1 (zh) | α相關疾病的治療 | |
AU2003258305A8 (en) | Combination therapy for treatment of fibrotic disorders | |
AU2003286567A8 (en) | Methods for the treatment of skin disorders | |
EP1489915A4 (de) | Behandlung und vorbeugung von entzündlichen erkrankungen | |
GB0201850D0 (en) | Therapeutic treatment | |
GB0216321D0 (en) | Therapeutic treatment | |
AU2003228819A8 (en) | Combinations for the treatment of inflammatory skin disorders | |
HK1078784A1 (en) | Therapeutic treatment | |
AU2003293099A8 (en) | Treatment of dna damage related disorders | |
GB0223367D0 (en) | Therapeutic treatment | |
GB0213869D0 (en) | The treatment of pain | |
GB0211295D0 (en) | Treatment of pain | |
AU2002359177A1 (en) | Use of interleukin-6 for treatment of obesity | |
AP2004003174A0 (en) | Treatment of water | |
GB0210741D0 (en) | Methods of therapy | |
GB0210464D0 (en) | Therapeutic treatment | |
EP1539100A4 (de) | Zusammensetzung und verfahren zur behandlung von hauterkrankungen | |
IL166062A0 (en) | Compositions and methods for therapeutic treatment | |
AU2003270540A8 (en) | Treatment of cyclooxygenase-3 mediated diseases and disorders | |
GB0217493D0 (en) | Novel methods of treatment | |
GB0221712D0 (en) | Methods of treatment | |
GB0216097D0 (en) | Treatment of proliferative disorders | |
AU2003293714A1 (en) | Methods for the treatment of chronic pain and compositions therefor | |
GB0222505D0 (en) | Treatment of pain | |
GB0210210D0 (en) | Treatment of hydrocarbons |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20230713 |